Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.

Clinical pharmacology in drug development - 1 May 2014

Elshoff Jan-Peer, Cawello Willi, Andreas Jens-Otto, Braun Marina

Abstract excerpt

Rotigotine, a non-ergolinic dopamine receptor agonist administered transdermally via a patch, is metabolized by several cytochrome P-450 (CYP450) isoenzymes, including CYP2C19. This open-label, multiple-dose study evaluated the effect of omeprazole, a competitive inhibitor of CYP2C19, on the pharmacokinetics of rotigotine and its metabolites under steady-state conditions in healthy male subjects (of the extensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Cutaneous
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Agonists

Share to Healthy Volunteers

Share to Omeprazole

Share to Pharmacogenomic Variants

Share to Proton Pump Inhibitors

Share to Thiophenes

Source

Identifiers

PMID: 27128608
DOI: 10.1002/cpdd.78

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.PMID 27128608Read ↗

Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity.Semantic proximity Read ↗

Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.Semantic proximity Read ↗

High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.Semantic proximity Read ↗

Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios.Semantic proximity Read ↗

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.Semantic proximity Read ↗

Omeprazole disposition in children following single-dose administration.Semantic proximity Read ↗

Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects.Semantic proximity Read ↗

Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.Semantic proximity Read ↗

Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1-1Δ.Semantic proximity Read ↗

The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.Semantic proximity Read ↗

Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers.Semantic proximity Read ↗

Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.